Published in Blood Weekly, September 26th, 2002
Ostex will now begin selling the Osteomark NTx Serum test, in the microtiter format, exclusively to Mochida for distribution in Japan.
Under the terms of the agreement with Mochida, the import approval from the Ministry of Health, Labor and Welfare (MHLW, formally Koseisho) triggers a $250,000 milestone payment from Mochida to Ostex.
Thomas Bologna, chairman, president, and CEO of Ostex stated, "Mochida has done an excellent job in establishing the NTx...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.